Allison Clemens
April
ababaabhay
achoi2392
adhoward1

2025 PACUPrep BCCCP Preparatory Course Thyroid Emergencies: Thyroid Storm & Myxedema Coma Advanced Pharmacotherapy in Thyroid Emergencies

Lesson 49, Topic 3

In Progress

← Previous

Advanced Pharmacotherapy in Thyroid Emergencies

Lesson Progress

0% Complete

Learning Objective

Effectively manage thyroid storm and myxedema coma using advanced pharmacotherapy, including appropriate drug selection, dosing, and monitoring.

1. Antithyroid Agents (Thionamides)

Summary: Thionamides stop new hormone production. Propylthiouracil (PTU) additionally blocks peripheral T4-to-T3 conversion, making it the first-line agent in thyroid storm.

Propylthiouracil (PTU)

Mechanism: Inhibits thyroid peroxidase (blocking hormone synthesis) and 5′-deiodinase (blocking peripheral T4 to T3 conversion).
Indications: Thyroid storm; first-trimester pregnancy.
Dosing (Thyroid Storm): 500–1,000 mg PO loading dose, followed by 250 mg PO every 4 hours. Adjust based on clinical response.
Monitoring: Baseline and weekly complete blood count (CBC) for agranulocytosis and liver function tests (LFTs) for hepatotoxicity.
Warnings: Carries a black box warning for severe liver injury. Avoid in patients with pre-existing severe hepatic dysfunction. Switch to methimazole after the first trimester of pregnancy.

Methimazole

Mechanism: Inhibits thyroid peroxidase only; does not block peripheral T4 to T3 conversion.
Indications: Alternative agent in non-pregnant patients or those not in severe storm; preferred agent for the second and third trimesters of pregnancy.
Dosing (Thyroid Storm): 60–80 mg per day PO, typically divided every 6–8 hours.
Monitoring: Baseline CBC and LFTs. Counsel patients on teratogenic risk.
Advantages: Longer half-life allows for less frequent dosing and generally lower cost.

Clinical Pearl: PTU and Liver Function +

Always obtain baseline LFTs before initiating PTU. Educate the patient and nursing staff on the signs of liver dysfunction (e.g., jaundice, dark urine, abdominal pain). Discontinue the drug immediately if significant transaminitis or clinical signs of liver injury develop.

2. Iodine Therapy

Summary: Inorganic iodide acutely inhibits the release of pre-formed thyroid hormone via the Wolff-Chaikoff effect. Timing of administration relative to thionamides is critical to prevent worsening thyrotoxicosis.

Agents and Dosing

Saturated Solution of Potassium Iodide (SSKI): 5 drops (approximately 250 mg iodide) PO every 6 hours.
Lugol’s Solution (5% iodine, 10% potassium iodide): 8 drops (approximately 50 mg iodide) PO every 8 hours.

Critical Administration Timing

Iodine therapy must be administered at least one hour after the loading dose of a thionamide (PTU or methimazole). Administering iodine first provides the thyroid gland with more substrate, which can paradoxically increase hormone synthesis and exacerbate the storm.

Monitoring

Watch for signs of hypersensitivity (rash, fever) or iodism (metallic taste, sore gums, gastrointestinal upset).

Clinical Pearl: Iodine Allergy Alternative +

In patients with a documented severe allergy to iodine, lithium carbonate can be considered as an alternative agent to block hormone release. The typical dose is 300 mg PO every 6 hours, with close monitoring of lithium levels and renal function.

3. Beta-Adrenergic Blockade

Summary: β-blockers are essential for controlling the severe adrenergic symptoms of thyroid storm (tachycardia, hypertension, tremor). The choice of agent depends on the patient’s hemodynamic stability and comorbidities.

Comparison of Beta-Blockers in Thyroid Storm
Agent	Dosing	Key Considerations
Propranolol	PO: 60–80 mg q4–6h IV: 1–2 mg q4h	Non-selective; also inhibits peripheral T4→T3 conversion. Use with caution in asthma/COPD. Titrate to HR < 100 bpm.
Esmolol	IV Infusion: Start 25–50 µg/kg/min; titrate by 25 µg/kg/min q10min (max 200 µg/kg/min)	β1-selective and ultra-short-acting. Ideal for hemodynamically unstable patients (e.g., decompensated heart failure) or when rapid titration is needed.

Clinical Pearl: Choosing the Right β-Blocker +

Use esmolol when rapid titration or a short duration of effect is paramount, such as in patients with suspected or confirmed decompensated heart failure where excessive beta-blockade could be detrimental. Once stable, the patient can be transitioned to an oral agent like propranolol.

4. Glucocorticoids

Summary: Stress-dose steroids are a critical adjunct in both thyroid storm and myxedema coma. They block peripheral T4-to-T3 conversion and provide crucial support for potential relative adrenal insufficiency, which can coexist with severe thyroid disease.

Hydrocortisone

Dosing in Thyroid Storm: 300 mg IV loading dose, followed by 100 mg IV every 8 hours. Taper over 2–3 days as the patient stabilizes.
Dosing in Myxedema Coma: 100 mg IV every 8 hours until concomitant adrenal insufficiency is ruled out with a cortisol level or stimulation test.
Monitoring: Blood glucose (hyperglycemia), signs of infection. Consider PJP prophylaxis for prolonged high-dose therapy.
Contraindications: Use with caution in patients with active systemic fungal infections.

Clinical Pearl: Steroid Timing is Key +

Administer glucocorticoids empirically before or concurrently with the first dose of antithyroid medication in thyroid storm, and before thyroid hormone replacement in myxedema coma. Waiting to treat potential adrenal insufficiency can be fatal.

5. Thyroid Hormone Replacement (Myxedema Coma)

Summary: The goal is to cautiously replace deficient hormone to restore metabolic function without precipitating cardiovascular collapse. Intravenous levothyroxine (T4) is the standard of care, with liothyronine (T3) reserved for refractory cases.

Comparison of Thyroid Hormones in Myxedema Coma
Agent	Dosing	Key Considerations
Levothyroxine (T4)	IV Load: 200–400 µg IV Maintenance: 75–100 µg q24h	Standard of care. Provides a steady pool for peripheral conversion to T3. Reduce initial dose (100–200 µg) in the elderly or those with known coronary artery disease.
Liothyronine (T3)	IV Load: 5–20 µg IV Maintenance: 2.5–10 µg q8h	Rapid-acting, potent. Use is controversial due to increased risk of arrhythmias and cardiac ischemia. Reserved for severe, refractory cases or when T4 conversion is impaired.

Clinical Pearl: Combined T4/T3 Therapy +

When using T3, it should be given concurrently with or after the initial T4 loading dose. Administering T3 alone can cause a precipitous drop in T4 levels, which may worsen cerebral edema. Monitor free T4 and T3 levels every 24-48 hours during initial replacement.

6. PK/PD and Administration Considerations

Summary: Critical illness significantly alters drug pharmacokinetics and pharmacodynamics. Adjustments to route and dosing are essential for efficacy and safety.

Absorption: For patients unable to take oral medications, thionamides can be crushed and administered via nasogastric (NG) tube. If enteral absorption is unreliable due to shock or ileus, switch to IV formulations where available (though thionamides are not).
Distribution: Hypoalbuminemia, common in critical illness, increases the fraction of free, active thyroid hormone. Monitoring free T4/T3 levels is more reliable than total levels.
Administration: Administer IV thyroid hormones (T4/T3) as a direct IV push rather than a continuous infusion to minimize drug adsorption to plastic tubing, which can lead to underdosing.
Organ Dysfunction: Reduce thionamide doses in patients with significant hepatic impairment and monitor LFTs closely. Renal dysfunction has less impact on thionamide clearance.

7. Clinical Decision Points & Controversies

Summary: While core principles are established, some areas of management remain debated, requiring individualized clinical judgment.

Controversy: PTU vs. Methimazole in Storm +

While PTU’s peripheral conversion blockade makes it theoretically superior, recent observational data suggest no significant mortality difference between PTU and methimazole in thyroid storm. The choice may be guided by availability, cost, and patient-specific risk factors (e.g., liver disease, pregnancy).

Controversy: Role of Plasmapheresis and T3 +

Plasmapheresis: This may be considered a rescue therapy in refractory thyroid storm to rapidly remove circulating thyroid hormones and antibodies, but its role and timing are not well-defined by high-quality evidence.
T3 Supplementation in Myxedema: Proponents argue it may hasten neurological recovery, while opponents highlight the significant risk of inducing life-threatening arrhythmias. Its use should be highly selective and reserved for patients failing to improve with T4 monotherapy.

8. Clinical Pearls & Practice Pitfalls

Successful management hinges on correct sequencing, aggressive monitoring, and interdisciplinary teamwork.

Figure 1: Critical Drug Sequencing in Thyroid Storm. The sequence of thionamide first, followed by iodine at least one hour later, is paramount to prevent worsening of the storm. Beta-blockers and steroids can be given concurrently with the thionamide.

Key Practice Points

Avoid Tubing Losses: Administer IV thyroid hormones via direct IV push to ensure the full dose is delivered.
Monitor Aggressively: In the acute phase, obtain daily CBC and LFTs for patients on thionamides. Continuous ECG monitoring is essential during IV hormone replacement in patients with cardiac disease.
Coordinate Care: Ensure clear communication between pharmacy, endocrinology, critical care, and nursing teams to facilitate timely drug administration and monitoring.

Key Takeaways

PTU is preferred in thyroid storm for its dual mechanism, but methimazole is an effective alternative.
Iodine therapy must follow thionamide administration by at least one hour to prevent exacerbation.
β-Blockers and stress-dose steroids are essential adjuncts to control symptoms and support adrenal function.
IV levothyroxine is the cornerstone of myxedema coma therapy; T3 is reserved for refractory presentations due to cardiac risk.

References

Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21(6):593–646.
Lee SY, Van den Anker J, Lee S, et al. Propylthiouracil vs methimazole for thyroid storm in critically ill patients. JAMA Netw Open. 2023;6(4):e238655.
Leung AM. Thyroid emergencies. J Infus Nurs. 2016;39(5):281–286.
Wall CR. Myxedema coma: diagnosis and treatment. Am Fam Physician. 2000;62(11):2485–2490.
Glinoer D, Cooper DS. The propylthiouracil dilemma. Curr Opin Endocrinol Diabetes Obes. 2012;19(5):402–407.
Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751.
Golombek SG, Escribano J, LaGamma EF, et al. Stability of thyroid hormones during continuous infusion. J Perinat Med. 2011;39(4):471–475.

2025 PACUPrep BCCCP Preparatory Course

Pulmonary

Participants 432

Advanced Pharmacotherapy in Thyroid Emergencies

Advanced Pharmacotherapy in Thyroid Emergencies

Learning Objective

1. Antithyroid Agents (Thionamides)

Propylthiouracil (PTU)

Methimazole

2. Iodine Therapy

Agents and Dosing

Critical Administration Timing

Monitoring

3. Beta-Adrenergic Blockade

4. Glucocorticoids

Hydrocortisone

5. Thyroid Hormone Replacement (Myxedema Coma)

6. PK/PD and Administration Considerations

7. Clinical Decision Points & Controversies

8. Clinical Pearls & Practice Pitfalls

Key Practice Points

Key Takeaways

References